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OBJECTIVE — The purpose of this study was to evaluate the 2-year pulmonary safety of
inhaled human insulin (Exubera [EXU]) in 635 nonsmoking adults with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Patients were randomly assigned to receive
prandial EXU or subcutaneous insulin (regular or short-acting) plus basal (intermediate- or
long-acting)insulin.Theprimaryendpointsweretheannualrateofdeclineinforcedexpiratory
volume in 1 s (FEV1) and carbon monoxide diffusing capacity (DLCO).
RESULTS — Small differences in FEV1 favoring subcutaneous insulin developed during the
ﬁrst3monthsbutdidnotprogress.AdjustedtreatmentgroupdifferencesinFEV1annualrateof
change were 0.007 l/year (90% CI 0.021 to 0.006) between months 0 and 24 and 0.000
l/year(0.016to0.016)duringmonths3–24.TreatmentgroupdifferencesinDLCOannualrate
of change were not signiﬁcant. Both groups sustained similar reductions in A1C by month 24
(last observation carried forward) (EXU 7.7–7.3% vs. subcutaneous insulin 7.8–7.3%). Reduc-
tions in fasting plasma glucose (FPG) were greater with EXU than with subcutaneous insulin
(adjusted mean treatment difference 12.4 mg/dl [90% CI 19.7 to 5.0]). Incidence of
hypoglycemia was comparable in both groups. Weight increased less with EXU than with
subcutaneous insulin (1.3 kg [1.9 to 0.7]). Adverse events were comparable, except for a
higher incidence of mild cough and dyspnea with EXU.
CONCLUSIONS — Two-year prandial EXU therapy showed a small nonprogressive differ-
ence in FEV1 and comparable sustained A1C improvement but lower FPG levels and less weight
gain than seen in association with subcutaneous insulin in adults with type 2 diabetes.
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nhaled human insulin (Exubera
[EXU], insulin human [rDNA origin]
inhalation powder) is effective in pa-
tients with type 2 diabetes in whom gly-
cemic control is not achieved with diet
and exercise (1) and provides better gly-
cemic control in patients whose diabetes
remains inadequately controlled with ei-
ther monoagent or combination oral
agent regimens (2–5). In addition,
6-month EXU therapy is at least compa-
rable in efﬁcacy to subcutaneous insulin
therapy in type 2 diabetes (6).
Previous controlled studies of EXU in
type2diabeticpatientshaveshownslight
but consistent treatment group differ-
ences in pulmonary function in favor of
comparators,usingnonstandardizedlung
functiontesting(3–6).Thesesmalldiffer-
ences occurred early, did not progress for
up to 2 years, and were not clinically
meaningful. However, these studies were
not designed speciﬁcally to examine re-
spiratory safety primary end points.
The aim of the present study was to
provide a robust evaluation of the long-
term pulmonary safety of EXU versus
subcutaneousinsulin.Adultpatientswith
type 2 diabetes were evaluated by means
of validated, highly standardized pulmo-
nary function testing, trained coordina-
tors, and centralized data collection (7–
10).Asecondaryobjectivewastoevaluate
the long-term efﬁcacy of EXU versus sub-
cutaneous insulin.
RESEARCH DESIGN AND
METHODS—This is an ongoing, ran-
domized, open-label, 5.5-year, parallel-
group study in 84 centers in the U.S.,
Canada, and Brazil. Data from the ﬁrst 2
years of treatment are reported here. The
protocol was reviewed and approved by
theindependentlocalinstitutionalreview
boards of all participating centers, and all
patients provided written informed con-
sent. The study is being conducted in ac-
cordancewiththeethicalprinciplesofthe
Declaration of Helsinki.
Patients who had type 2 diabetes for
at least 1 year, were aged 35–75 years,
were receiving a stable subcutaneous in-
sulin regimen for at least 2 months, and
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2, A1C levels of 5.5–
11%, and fasting plasma C-peptide con-
centrations 0.2 pmol/ml (0.6 ng/ml)
were eligible for inclusion. Patients were
excluded if they had unstable diabetes or
recurrent severe hypoglycemia, poorly
controlledasthma,signiﬁcantchronicob-
structive pulmonary disease or other re-
spiratorydisease,abnormallungfunction
tests (forced expiratory volume in 1 s
[FEV1] 70% of predicted, carbon mon-
oxide diffusing capacity [DLCO] 120%
or 70% of predicted, or total lung ca-
pacity [TLC] 130% or 70% of pre-
dicted)oriftheyhadreportedsmokingin
the previous 6 months. The predictive
equations of Hankinson et al. (11), Crapo
etal.(12),andMilleretal.(13)wereused
to establish baseline percent predicted
lung function for FEV1, TLC, and DLCO,
respectively. A 12% adjustment in TLC
and DLCO predicted values was applied
for subjects of self-reported black race.
After a 4-week run-in, during which
allpatientsoptimizedsubcutaneousinsu-
lin use, patients were randomly assigned
at week 0 to receive either subcutaneous
insulin (regular or a short-acting analog)
or prandial EXU, both in combination
with intermediate- or long-acting insulin
(NPH insulin, Ultralente, or insulin
glargine). Randomization was performed
using a computer-generated schedule.
EXU was administered within 10 min be-
fore meals. The initial dose was based on
body weight, and subsequent doses were
adjusted to achieve blood glucose con-
centrationsof80–120mg/dlbeforemeals
and 100–140 mg/dl at bedtime.
Primary end points were the annual
rates of decline for FEV1 and DLCO. Pul-
monary function tests were performed at
screening, weekly for 3 weeks before ran-
domized treatment was started and after
3, 6, 9, 12, 15, 18, 21, and 24 months of
treatment. Baseline pulmonary function
was deﬁned as the means of the values
obtained after screening and before ran-
domization(weeks2and1).Thepul-
monary function tests used validated,
highlystandardizedmethodology(7–10).
All study coordinators performing pul-
monary function tests underwent a 2-day
training session and were required to
show theoretical and practical competen-
cies before performing any tests. The
same type of lung function analyzer (Col-
lins CPL; Collins Medical, Braintree, MA)
was used at all centers to minimize inter-
machine variability. All testing was per-
formed according to American Thoracic
Societyguidelines(14,15).Datawerecol-
lected centrally at Ferraris Respiratory
(Louisville, CO) and assessed for quality.
Secondary end points for efﬁcacy as-
sessments included A1C, fasting plasma
glucose (FPG), hypoglycemic events, in-
sulin dose, and body weight. Baseline for
A1C, FPG, and body weight was deﬁned
as the average of all measurements after
screening and before the ﬁrst dose of
study drug. Baseline insulin dose was the
week0doseofsubcutaneousinsulin.Hy-
poglycemia and severe hypoglycemia
weredeﬁnedasdescribedbyHollanderet
al. (6).
Safetywasassessedbymonitoringad-
verse events and clinical laboratory test-
ing. Serum samples for measurement of
insulin antibodies were obtained at base-
line;atweeks3,6,12,and18;atmonth6;
and at 3-month intervals thereafter. Dys-
pneawasassessedinallpatientsbymeans
of the baseline (BDI) and transition dys-
pnea index (TDI) (16). The BDI was es-
tablished 1 week before treatment was
started, and the TDI was established after
4 and 12 weeks of treatment and at 6, 12,
18, and 24 months.
Statistical analysis
Thistrialwasdesignedtoestimatethedif-
ference in annual rates (slopes) of lung
function decline between EXU and sub-
cutaneous insulin. The datasets, models,
andproceduresusedhavebeendescribed
previously (17). It was estimated that a
sample size of 243 patients per group
would allow determination of the
between-treatment group differences in
theannualdeclineinlungfunctionwitha
precision of 22.4 ml/year for FEV1 and
0.4 ml   min
1   mmHg
1   year
1 for
DLCO. This estimate was based on a two-
sided 90% CI, assuming standard devia-
tionsfortheannualizedratesofdeclineof
150 ml for FEV1 and 2.5 ml   min
1  
mmHg
1 for DLCO. The precision was
also based on the normal approximation
of the test statistic for the comparison be-
tween two means.
RESULTS—A total of 635 patients
were randomly assigned to either EXU
(n319)ortosubcutaneousinsulin(n
316). Three patients in the EXU group
and ﬁve in the subcutaneous insulin
group withdrew before receiving the
study treatment. Of the remaining pa-
tients, 225 in the EXU group and 237 in
the subcutaneous insulin group com-
pleted 2 years of treatment (supplemental
Fig.A1,availableinanonlineappendixat
http://dx.doi.org/10.2337/dc08-0159).
Demographicsofthepatientsatscreening
are summarized in Table 1. The two
groups were well matched in terms of de-
mographic characteristics, duration of di-
Table 1—Patient characteristics at screening (week 4)
EXU
Subcutaneous
insulin
Sex (male/female) 205/111 (65/35) 193/118 (62/38)
Race
White 234 (74.1) 222 (71.4)
Black 28 (8.9) 28 (9.0)
Asian 6 (1.9) 6 (1.9)
Hispanic 38 (12.0) 42 (13.5)
Other 10 (3.2) 13 (4.2)
Age (years) 56.7  9.2 55.5  9.9
Weight (kg) 87.1  14.8 88.3  15.4
Height (cm) 171.0  9.7 170.9  10.1
BMI (kg/m
2) 29.6  4.0 30.1  3.9
A1C (%) 8.02  1.26 8.15  1.30
C-peptide (pmol/ml) 0.43  0.37 0.36  0.25
Time since diagnosis of diabetes (years) 13.7 (0.7–43.3) 13.7 (0.5–40.2)
FEV1*
Observed (liters) 2.91  0.68 2.93  0.71
Predicted (%) 90.9  11.8 91.2  12.6
DLCO*
Observed (ml   min
1   mmHg
1) 24.17  5.58 23.99  5.72
Predicted (%) 92.3  14.1 91.5  12.7
Dataaren(%),meansSD,ormean(range).*FEV1andDLCOtestvaluesatstudyentryweredeﬁnedasthe
means of the values obtained at weeks 2 and 1.
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glycemiccontrol.Themajorityofpatients
were using insulin lispro or insulin aspart
at baseline (EXU 65.9%; subcutaneous
insulin 72.4%), and most were injecting
three times per day. At randomization,
41.9% of EXU and 39.8% of subcutane-
ous insulin patients were taking insulin
glargine as their basal insulin.
Pulmonary function
Small decreases from baseline in FEV1
were observed in both treatment groups
(Fig. 1A). The mean  SE changes in
FEV1 from baseline at 2 years (last obser-
vation carried forward [LOCF]) were
0.121  0.013 l in the EXU group and
0.099  0.012 l in the subcutaneous
insulin group, giving an adjusted mean
treatment difference (EXU  subcutane-
ous insulin) of0.023 l (90% CI0.047
to 0.002). These mean differences were
not driven by outlier EXU-treated sub-
jects with large declines in FEV1 (data not
shown). Comparison of the mean annu-
alized rates of change in FEV1 from base-
linetomonth24andfrommonths3to24
showed that the treatment group differ-
enceoccurredduringtheﬁrst3monthsof
treatmentanddidnotprogressthereafter.
Speciﬁcally, the mean annual rates of
change for up to 24 months were
0.069  0.006 l/year in the EXU group
and 0.061  0.006 l/year in the subcu-
taneous insulin group, giving an adjusted
treatment group difference of 0.007
l/year (90% CI 0.021 to 0.006). From
months3to24,thecorrespondingﬁgures
were 0.058  0.007 and 0.058 
0.006 l/year in EXU- and subcutaneous
insulin–treatedsubjects,respectively(ad-
justed treatment group difference 0.000
l/year [90% CI 0.016 to 0.016]).
Mean changes in DLCO are shown in
Fig. 1B. At 2 years (LOCF), the changes
from baseline were 0.661  0.134 ml  
min
1   mmHg
1 in the EXU group and
0.8260.130ml min
1 mmHg
1in
the subcutaneous insulin group, giving a
mean treatment difference of 0.165 ml  
min
1   mmHg
1 (90% CI 0.102 to
0.432). The adjusted annual rates of
changeinDLCOforupto24monthswere
0.343  0.067 ml   min
1   mmHg
1  
year
1 in the EXU group and 0.385 
0.063 ml   min
1   mmHg
1   year
1 in
the subcutaneous insulin group, giving a
mean treatment difference of 0.042 ml  
min
1   mmHg
1   year
1 (90% CI
0.109 to 0.193). The corresponding
ﬁgures from months 3 to 24 were
0.192  0.077 and 0.292  0.071
ml   min
1   mmHg
1   year
1 in EXU
and subcutaneous-treated subjects, re-
spectively (mean treatment difference
of 0.100 ml   min
1   mmHg
1   year
1
[90% CI 0.072 to 0.273]).
Efﬁcacy
Glycemiccontrolwassustainedandcom-
parable in both groups (Fig. 2A). The
mean treatment group difference in A1C
at month 24 was small (Table 2) and was
consistentwithnoninferiorityusingcrite-
ria similar to those used in earlier EXU
efﬁcacy trials (upper bound of CI
0.5%). Although the mean observed
values of FPG were comparable at base-
line, decreases in FPG were consistently
greaterwithEXUthanwithsubcutaneous
insulin at all subsequent time points (Fig.
2B; Table 2). Body weight increased in
both groups, but the weight gain increase
was signiﬁcantly attenuated with EXU
compared with subcutaneous insulin
(Fig. 2C; Table 2).
The incidence of hypoglycemic
eventsdeclinedovertimeandwasslightly
lower with EXU than with subcutaneous
insulin,witha22%riskreduction(0.8vs.
1.0 events per subject-month, respec-
tively; risk ratio 0.78 [90% CI 0.75-
0.80]). The incidence of severe
hypoglycemic events was similar with
EXU and subcutaneous insulin (0.4 vs.
0.6 events per 100 subject-months, re-
spectively; 0.68 [0.44–1.06]).
Safety
A total of 2,126 adverse events occurred
in 315 (99.7%) patients in the EXU
group, and 2,069 events occurred in 303
(97.4%) patients in the subcutaneous in-
sulin group. Overall, 22 patients (7%) in
the EXU group and 4 (1.3%) in the sub-
cutaneous insulin group discontinued
treatment because of adverse events (Fig.
A1). Twelve of the adverse events result-
ing in discontinuation in the EXU group
were judged to be treatment related and
included cough (n  7), asthma exacer-
bation (n  3), weight gain (n  1), and
dyspnea (n  1). None of the adverse
events that resulted in discontinuation in
Figure 1—Mean change in FEV1 (A) and DLCO (B) from baseline. Treatment group difference:
EXU  subcutaneous insulin (SC).
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related.
The adverse event proﬁles of the two
groups were comparable, except for a
higher incidence of cough in EXU-treated
patients. The incidence of cough was
highest during the ﬁrst 3 months of treat-
ment in the EXU group (23.1%) and de-
creased during subsequent 3-month
periods (Table A1, available in the online
appendix). Dyspnea was reported in
5.4%ofEXU-treatedpatients(2.5%treat-
ment related) and 3.5% (0.3% treatment
related) of patients receiving subcutaneous
insulin. Mean  SD BDI total scores were
10.99  1.70 and 11.05  1.65, respec-
tively, and changes in TDI total scores at 2
years were 0.10  0.63 and 0.01 
0.75, respectively.
Ninety-eight subjects in each treat-
ment group underwent high-resolution
computerizedtomography(HRCT)ofthe
thorax at baseline and at least one post-
baseline visit. For subjects with normal
baseline scans, the incidence of abnormal
HRCT results was comparable between
treatment groups at month 24. For sub-
jectswithabnormalbaselinescans,noad-
ditional worsening of HRCT results
occurred in subjects in the EXU group at
month 24 (Table A2, available in the on-
line appendix).
Median insulin antibody concentra-
tions at baseline were 1.05 U/ml in both
groups. At 2 years, the median changes
from baseline were 10.6 U/ml in the
EXU group and 0.0 U/ml in the subcu-
taneous insulin group. No correlation be-
tween insulin antibodies and A1C, FPG,
frequency of hypoglycemia, or insulin
doses was observed.
CONCLUSIONS —This is the ﬁrst re-
port of long-term pulmonary safety in in-
sulin-using type 2 diabetic patients
receivingEXU.Usinghighlysensitiveand
precise validated methods to assess pul-
monary function (7–10), small, clinically
nonmeaningful treatment group differ-
ences in the change in FEV1 during the
ﬁrst 3 months of treatment favoring sub-
cutaneous insulin were identiﬁed, con-
ﬁrming previous ﬁndings with EXU in
type 2 diabetic patients (3–6). Most nota-
bly, the between-group differences did
not increase after 3 months for up to 2
years, and pulmonary function declined
at similar rates in both groups during
months 3 to 24, reﬂecting an age- or dia-
betes-related decline in pulmonary func-
tion (18). The mechanism of the early
treatment effect of EXU on FEV1 is un-
known and remains under study. No sig-
niﬁcant difference in the annual rate of
change in DLCO was observed between
the two treatment groups.
The annualized decline in FEV1 in
both the EXU and subcutaneous insulin
groups between months 3 and 24
(0.058 l/year) was greater than that re-
portedinthegeneralpopulation(0.040
l/year) (19,20), adding to the growing lit-
erature suggesting that reduced lung
function is a chronic complication of type
2 diabetes. In a prospective study of 125
type 2 diabetic patients, FEV1 decreased
by a mean of 0.071 l/year (21), and his-
topathological changes have been re-
ported in the lungs of patients with
diabetes in preliminary studies (22,23).
Althoughrespiratorydysfunctionisrarely
apresentingcomplaint(24),furtherstud-
ies are warranted to understand the im-
pact of diabetes on lung function.
Figure 2—Adjusted mean adjusted change in A1C (A), FPG (B), and body weight (C) from
baseline.
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that the treatment targets were not met,
anditisconceivablethatthemeanA1Cof
7.3% would have been lower if a more
structured insulin titration algorithm was
used. Despite comparable levels of long-
term A1C control and slightly less hypo-
glycemia, EXU therapy was also
associated with greater reductions in FPG
levels and signiﬁcantly less weight gain
than subcutaneous insulin over 2 years.
This FPG ﬁnding has been observed in
previous EXU studies (6,17) and may be
related to EXU pharmacokinetics such
that prandial use reduces late postpran-
dialhyperglycemiaafterdinner,improves
overnight glucotoxicity, and reduces he-
patic glucose production.
Adverse events in the two treatment
groups were similar except for a higher
incidenceofcoughintheEXUgroupdur-
ing the ﬁrst 3–6 months of treatment,
with incidence decreasing during subse-
quent 3-month periods. Cough tended to
occur within minutes after inhalation,
was usually mild in severity, and was sel-
dom productive. Dyspnea was rare in
both groups, although the incidence was
higher in EXU-treated patients than in
those receiving subcutaneous insulin.
The majority of dyspnea episodes were
mild, and the index scores indicate that
patients seldom experienced dyspnea
during everyday activities and that no
clinically signiﬁcant increases in dyspnea
occurred during treatment (25). For sub-
jects who underwent HRCT scans, the in-
cidence of abnormal HRCT results was
comparable between treatment groups
and did not worsen up to month 24.
Insulin antibody formation was more
marked after administration of EXU than
after subcutaneous insulin administra-
tion, a ﬁnding consistent with those of
previous studies (26). However, antibody
formation in response to EXU was not
correlated with glycemic control, insulin
dose, hypoglycemic episodes, change in
FEV1, or tolerability (26,27). Recently, in
a3-month,highlystandardizedtype1di-
abetes study, no association was found
between the time course of changes in
lung function and antibody responses, ei-
ther at the beginning or on discontinua-
tion of EXU therapy (28).
In summary, 2-year prandial EXU
therapy showed a small nonprogressive
difference in FEV1 and comparable sus-
tained A1C improvement but lower FPG
levels and less weight gain than seen in
association with subcutaneous insulin in
adults with type 2 diabetes.
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